New biomarker helps differentiate underlying pathologies of frontotemporal lobar degenerationResearchers at the Alzheimer Center Amsterdam (Amsterdam UMC) have published a study on a novel cerebrospinal fluid biomarker, AcTau174, in Nature Medicine. In this study, neuroscientists Madison Honey, Charlotte Teunissen, and colleagues show that AcTau174 concentrations are elevated across multiple neurodegenerative diseases, including two forms of frontotemporal dementia (FTD), Alzheimer’s disease (AD), mild cognitive impairment due to AD (MCI-AD), and dementia with Lewy bodies (DLB). Importantly, they demonstrate that AcTau174 concentrations can differentiate between underlying pathologies in FTD.
How does your DNA make your brain unique?Brains are not only shaped by our experience, but also by our genes. A new study led by neuroscientists Bernardo Maciel and Martijn van den Heuvel, from the Center for Neurogenomics and Cognitive Research (CNCR) at VU Amsterdam, found that at least one-third of our brain connections are heritable.
ZonMw Grant for a study into blood-based biomarker profiles to predict delayed ischemia after brain hemorrhageDagmar Verbaan, Professor of Evidence-Based Neurosurgery at Amsterdam UMC and Program Leader of the Neurovascular Disorders Program at Amsterdam Neuroscience, has been awarded a ZonMw Open Competition Grant. Together with colleagues she received nearly one million euros for their LIQUID-DCI project, which aims to investigate blood-based biomarkers to predict delayed cerebral ischemia (DCI) in patients with brain hemorrhage.
